Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells

Blood

Volumn 114, Issue 19, 2009, Pages 4179-4185

  Sharma, Sanjai ^a   Lichtenstein, Alan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; COMPLEMENTARY DNA; DACTINOMYCIN; EMETINE; LUCIFERASE; MESSENGER RNA; PROTEIN RENT 1; REGULATOR PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN;

ALTERNATIVE RNA SPLICING; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; E CADHERIN GENE; EXON; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENT 1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON; TUMOR SUPPRESSOR GENE;

EID: 77950524963     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-206482     Document Type: Article

References (33)

1. Montserrat E, Rozman C. Chronic lymphocytic leukemia: present status. Ann Oncol. 1995;6:219-235.
2. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol. 1998;25:42-59.
3. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46: 219-234.
4. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101: 4944-4951.
5. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98: 181-186.
6. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
7. Culbertson MR. RNA surveillance: unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet. 1999; 15:74-80.
8. Frischmeyer PA, van Hoof A, O'Donnell K, Guerrerio AL, Parker R, Dietz HC. An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science. 2002;295: 2258-2261.
9. Gilad S, Khosravi R, Shkedy D, et al. Predominance of null mutations in ataxia-telangiectasia. Hum Mol Genet. 1996;5:433-439.
10. Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene: Breast Cancer Information Core. Hum Mutat. 1996;8:8-18.
11. Noensie EN, Dietz HC. A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat Biotechnol. 2001;19: 434-439.
12. Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK. Manipulation of nonsense mediated decay identifies gene mutations in colon cancer cells with microsatellite instability. Oncogene. 2004;23:639-645.
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
14. Peæina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003;3:17.
15. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science. 2004;303:1483-1487.
16. Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:3118-3123.
17. Boyd JM, Gallo GJ, Elangovan B, et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene. 1995;11:1921-1928.
18. Guan KL, Butch E. Isolation and characterization of a novel dual specific phosphatase, HVH2, which selectively dephosphorylates the mitogen-activated protein kinase. J Biol Chem. 1995;270: 7197-7203.
19. Gehring NH, Kunz JB, Neu-Yilik G, et al. Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements. Mol Cell. 2005; 20:65-75.
20. Sadot E, Simcha I, Shtutman M, Ben-Ze'ev A, Geiger B. Inhibition of β-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci U S A. 1998;95:15339-15344.
21. Simcha I, Kirkpatrick C, Sadot E, et al. Cadherin sequences that inhibit β-catenin signaling: a study in yeast and mammalian cells. Mol Biol Cell. 2001;12:1177-1188.
22. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents β-catenin nuclear localization and β-catenin/LEF-1-mediated transactivation. J Cell Sci. 1999;112:1237-1245.
23. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res. 2006;66:653-658.
24. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays. 2006;28: 378-386.
25. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol. 1999;17:1097-1100.
26. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108: 171-182.
27. Hammes A, Guo JK, Lutsch G, et al. Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell. 2001;106:319-329.
28. Steinman HA, Burstein E, Lengner C, et al. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem. 2004;279:4877-4886.
29. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood. 2000;95:3208-3213.
30. Black DL. Mechanisms of alternative premessenger RNA splicing. Annu Rev Biochem. 2003;72:291-336.
31. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007;14:185-193.
32. Shi J, Hu Z, Pabon K, Scotto KW. Caffeine regulates alternative splicing in a subset of cancer-associated genes: a role for SC35. Mol Cell Biol. 2008;8:883-895.
33. Merdzhanova G, Edmond V, De Seranno S, et al. E2F1 controls alternative splicing pattern of genes involved in apoptosis through up-regulation of the splicing factor SC35. Cell Death Differ. 2008;12:1815-1823.